Aatmaj Health (AATMAJ)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹26.75 |
| Market Cap | ₹60.46 Cr |
| P/E Ratio | 56.5 |
| ROCE | 3.39% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | 64.52% |
| Debt/Equity | — |
| Sales Growth | 27.03% |
| Promoter Holding | 64.33% |
| 52-Week Range | ₹16.7 — ₹26.75 |
| Sector | Healthcare Services |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Let me look at Aatmaj Health the way I would any business. It is a hospital, a sector I understand, but the figures on the table are a mixed bag. At ₹19.70, the market values this at only ₹47 crore. That is a tiny enterprise, and in hospital business small size is often a disadvantage. There is no dividend, no book value figure, and return on capital employed is just 3.39%. That is far below what I would demand from a business with pricing power and a durable moat. The latest quarter shows sales of ₹11 crore and net profit of ₹1 crore, which is decent, but a single quarter does not make an investment. It is growing: sales up 27% and profit up 64.5%. That sounds wonderful, but at a P/E of 56.5, the market is already paying for years of excellent performance. At that price, even good growth can leave you with poor returns. The PEG ratio of 1.23 is a bit kinder, but with so many financials missing—ROE, book value, debt-equity—I cannot judge the quality of the balance sheet. The Piotroski score of 7 out of 9 does suggest the operating health has improved, and promoter holding at 64.33% is a positive sign; they are aligned. But with a 52-week range of ₹16.70 to ₹25.50, the stock trades near the middle, and I see no margin of safety. I would not call this a Buffett-style purchase. It is a small, fast-growing hospital with good momentum but heavy valuation and incomplete disclosure. I would put it on the watch list, not in the wallet.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer